Outcomes of hemodiafiltration based on Japanese dialysis patient registry

Citation
S. Nakai et al., Outcomes of hemodiafiltration based on Japanese dialysis patient registry, AM J KIDNEY, 38(4), 2001, pp. S212-S216
Citations number
9
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Urology & Nephrology
Journal title
AMERICAN JOURNAL OF KIDNEY DISEASES
ISSN journal
0272-6386 → ACNP
Volume
38
Issue
4
Year of publication
2001
Supplement
1
Pages
S212 - S216
Database
ISI
SICI code
0272-6386(200110)38:4<S212:OOHBOJ>2.0.ZU;2-0
Abstract
Effectiveness of various therapeutic modalities was analyzed among 1,196 pa tients entered in the registry of the Japanese Society for Dialysis Therapy who were on hemopurification therapy as of the end of 1998 and developed d ialysis-related amyloidosis during 1999. In the investigation, the effectiv eness of various hemopurification modalities on the dialysis-related amyloi dosis was ranked as exacerbation, unchanged, or alleviation, so as to analy ze the possible relationship between the hemopurification modality and Its effectiveness. The analysis was performed using a logistic regression appro ach, and the results were shown as "the risk of a worse therapeutic ranking " among the hemopurification modalities. The smaller "the risk of a worse t herapeutic effect" was, the more effective the treatment modality. When the risk of a worse therapeutic effect for the hemodialysis patients treated b y a regular membrane was put at 1.0, the risk for hemodialysis patients usi ng high-flux membrane was 0.489, the off-line hemodiafiltration risk was 0. 117, the on-line hemodiafiltration risk was 0.013, and the risk of push/pul l hemodiafiltration was 0.017. For hemodialysis with a beta (2)-microglobul in adsorption column, a low risk of 0.054 was found. The results indicated that hemodiafiltration therapy and simultaneous hemodialysis with beta (2)- microglobulin adsorption therapy were more effective treatment for dialysis -related amyloidosis. (C) 2001 by the National Kidney Foundation, Inc.